George Uy

67 year

Health Technology

Consumer Services

Profile

George Uy worked as an Executive Director of Marketing at Abraxis BioScience, Inc. He then worked as a Vice President of Sales & Marketing at Spectrum Pharmaceuticals, Inc. from 2007 to 2011.
Later, he worked as a Chief Commercial Officer & Executive VP at Sorrento Therapeutics, Inc. from 2013 to 2015.
Mr. Uy received his undergraduate degree from Cebu Institute of Medicine.

Former positions of George Uy

Companies	Position	End
SORRENTO THERAPEUTICS, INC.	Corporate Officer/Principal	2015-07-30
SPECTRUM PHARMACEUTICALS, INC.	Sales & Marketing	2011-05-31
Abraxis BioScience, Inc. Abraxis BioScience, Inc. Pharmaceuticals: MajorHealth Technology Abraxis Bioscience, Inc. develops therapeutics for cancer, infectious diseases and other critical illnesses. Its development platform uses nanoparticle albumin-bound technology to deliver drugs to tumors that produce SPARC. Abraxene, the first protein-based nanoparticle chemotherapeutic compound, is FDA approved for treating metastatic breast cancer. Abraxis Bioscience is focused on expanding the use of Abraxene and developing other drug candidates utilizing the same technology. Abraxene is approved for marketing in over 35 countris and the company has manufacturing facilities in the United States and Switzerland. Abraxis Bioscience was organized in 2007 from the oncology and research businesses of American Pharmaceutical Partners, Inc. and is headquartered in Los Angeles, CA.	Sales & Marketing	-

See the detail of George Uy's experience

Training of George Uy

Cebu Institute of Medicine

Undergraduate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of George Uy's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	2
SPECTRUM PHARMACEUTICALS, INC.	Health Technology
SORRENTO THERAPEUTICS, INC.	Health Technology

Private companies	1
Abraxis BioScience, Inc. Abraxis BioScience, Inc. Pharmaceuticals: MajorHealth Technology Abraxis Bioscience, Inc. develops therapeutics for cancer, infectious diseases and other critical illnesses. Its development platform uses nanoparticle albumin-bound technology to deliver drugs to tumors that produce SPARC. Abraxene, the first protein-based nanoparticle chemotherapeutic compound, is FDA approved for treating metastatic breast cancer. Abraxis Bioscience is focused on expanding the use of Abraxene and developing other drug candidates utilizing the same technology. Abraxene is approved for marketing in over 35 countris and the company has manufacturing facilities in the United States and Switzerland. Abraxis Bioscience was organized in 2007 from the oncology and research businesses of American Pharmaceutical Partners, Inc. and is headquartered in Los Angeles, CA.	Health Technology